Intravitreal Bevacizumab (Avastin) in Treatment of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy

Abstract

OBJECTIVE: To evaluate the role of intravitreal bevacizumab (Avastin) in treatment of vitreous hemorrhage due to proliferative diabetic retinopathy. METHODS: This quasi-experimental trial was conducted at department of Ophthalmology Khairpur Medical College, Khairpur Mir?s from January 2016 to June 2016. A number of 30 eyes of 30 patients having vitreous hemorrhage were selected and given intravitreal injection of bevacizumab 1.25 mg/ 0.05ml. Main outcome improvement in visual acuity with Snellen chart was observed at one week, four week and three months. RESULTS: Among 30 eyes visual acuity improved in 4 eyes (13.33%) in 1st week, 24 eyes 80%, improve within four weeks, at the end of 3 months 25(83.33%) eyes improve in visual acuity, while 5 eyes (16.66%) developed recurrent vitreous hemorrhage. CONCLUSION: In our study the Intravitreal bevacizumab produced partial or complete resolution of vitreous hemorrhage due to Proliferative Diabetic Retinopathy. Which is more useful in recent onset of hemorrhage. It is my suggestion that it can be a fine alternative of surgery.